In our study of patients with advanced or metastatic CRPC, MSS CRC, and PD-(L)1–refractory NSCLC, the ORR associated with the combination of navarixin plus pembrolizumab was lower than that previously reported in patients treated with pembrolizumab monotherapy. The gene discussed is CD274; the disease is non-small cell lung carcinoma.